Archive · 22 Aug 2025
Eris Lifesciences Gets GST Notice Over Novartis Trademark Deal
Imagine a company, Eris Lifesciences, that bought the trademark for a medicine brand called 'Zomelis' from a company in Switzerland.
The government has sent a notice saying Eris didn't pay a specific type of tax called IGST on this deal.
This tax is related to importing services.
The amount they owe is around ₹16.84 crore, plus some extra interest.
Eris says they always follow the rules and believes they have a good reason for not paying.
They are now talking to their tax experts to figure out how to respond to the government's notice.
Eris Lifesciences received a GST notice from DGGI, Mumbai.
The notice concerns the acquisition of 'Zomelis' trademark rights from Novartis.
The alleged non-payment of IGST under reverse charge mechanism is the reason.
The financial implication is an IGST of ₹16.84 crore plus interest.
Eris is evaluating the matter and will respond with its tax consultants.
- Who
- Eris Lifesciences and DGGI, Mumbai are the involved parties.
- What
- Eris Lifesciences received a show cause notice regarding non-payment of IGST.
- When
- The notice was received on or before August 22.
- Where
- The notice was issued by DGGI, Mumbai.
- Why
- The notice alleges non-payment of IGST related to the acquisition of a trademark.
Eris Lifesciences View
Government View
Compliance
Eris Lifesciences View
Eris Lifesciences believes it has complied with GST provisions.
Government View
N/A
- Company
- Eris Lifesciences
- Notice Issuer
- DGGI, Mumbai
- Subject
- GST non-payment
- Trademark Involved
- 'Zomelis'
- Amount
- ₹16.84 crore IGST
- Interest
- 18% per annum from Nov 27, 2019